Evidence map›Paper›PMID 42427842›Full record

ArticleResearch square2026

Baseline gene expression and dynamic endocrine therapy use in ER+ breast cancer: associations with recurrence in a real-world cohort.

Veronica Jones, Yongzhe Wang, Christine Quinones, Dana Aljaber, Eva Nelson, Aritro Nath, Irene Kang, Hope Rugo, Lisa Yee, Victoria Seewaldt and 1 more

Abstract readPreprint
In one paragraph

Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Veronica JonesCity Of Hope National Medical Center.
Yongzhe WangCity of Hope.ORCID 0009-0006-8771-7451
Christine QuinonesCity Of Hope National Medical Center.
Dana AljaberUniversity of California, Davis.
Eva NelsonUniversity of California, Riverside.
Aritro NathCity of Hope National Medical Center.ORCID 0000-0002-3225-4203
Irene KangCity of Hope National Medical Canter.
Hope RugoCity of Hope National Medical Canter.
Lisa YeeCity of Hope Comprehensive Cancer Center.ORCID 0000-0001-8243-1055
Victoria SeewaldtCity of Hope National Medical Canter.
Joanne MortimerCity of Hope.

Funding

Project 2U54CA285116 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI ERNEST MARTINEZ, Victoria L. Seewaldt · 2023 to 2026
$6.8M
NCI NIH HHS U54 CA285116
6 · The paper itself

Abstract

Endocrine therapy (ET) selection in estrogen receptor-positive breast cancer (ER + BC) is guided by menopausal status and tolerability rather than tumor biology, despite substantial heterogeneity in recurrence. We hypothesized that baseline gene expression differentially associates with recurrence depending on initial ET class. In a retrospective cohort of 74 ER+/HER2- patients treated with adjuvant ET, we profiled baseline tumor RNA and fitted adjusted Cox models for gene and ET interactions on time-to-recurrence and time-to-switch. Among selective estrogen receptor modulators-initiated patients, higher expression of

Indexed as

Endocrine therapyendocrine therapy switchingEstrogen Receptor-positive breast cancergene expressionrecurrenceside effect

Identifiers

PMID42427842
PMCPMC13345549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.